When we're talking about an intellectual property regime for brand-name drugs, we need to look at the period of market exclusivity, so, yes, in terms of patent protection, exclusivity, etc., but also how much we're paying in terms of prices while it's under market exclusivity.
The idea, or the wisdom, is that in Europe they have longer protection and lower prices. It's just longer protection. They don't have a patent linkage system in Europe. We do have it in Canada.
What it means is that for all the blockbuster drugs this patent linkage system is being used in order to introduce further delays. We're talking usually about a year, a year and a half of further delays.
In the end, when you look especially at the blockbuster drugs, they benefit from the same market exclusivity, be it in Europe or be it in Canada.